- Home
- FTHM vs EVAX Comparison
FTHM vs EVAX Comparison
Compare FTHM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | EVAX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 31.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FTHM | EVAX |
|---|---|---|
| Price | $0.73 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 69.5K | 31.4K |
| Earning Date | 03-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,184,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $1.20 |
| 52 Week High | $3.37 | $12.15 |
Technical Indicators
Market Signals| Indicator | FTHM | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 54.68 |
| Support Level | N/A | $2.45 |
| Resistance Level | $1.49 | $6.74 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 12.94 | 52.80 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.